By Talking Health TV –

A ground-breaking new cancer treatment is now being rolled out on the NHS, and it’s giving fresh hope to thousands of people across England living with a serious form of blood cancer.

The treatment, known as belantamab mafodotin (also called Blenrep), has been approved for use in the NHS by the National Institute for Health and Care Excellence (NICE). England is now the first country in the world to offer this innovative “Trojan horse” therapy to patients with multiple myeloma, a cancer that affects bone marrow.

Multiple myeloma is an aggressive and currently incurable cancer, but this new treatment is changing the outlook. Belantamab mafodotin works by targeting cancer cells directly and delivering a toxic payload from inside, much like the legendary Trojan horse from Greek mythology. The drug latches onto cancer cells, sneaks inside, and then unleashes a powerful anti-cancer agent that destroys them from within.

A Game-Changer for Patients

The treatment is delivered as an infusion every three weeks, in combination with two other drugs bortezomib and dexamethasone. In clinical trials, this powerful combination tripled the average time it takes for the cancer to progress, compared to current standard treatments.

Around 1,500 patients each year in England are expected to benefit from the new therapy. It will be offered to people whose cancer has either returned or failed to respond to earlier treatment options.

Paul Silvester, 60, from Sheffield, was one of the first to benefit through an early access programme. Diagnosed in 2023, he saw his cancer go into remission within weeks of receiving belantamab mafodotin.

“It feels like this treatment has brought the party balloons back in the house,” said Paul. “It’s been amazing.”

Community and Expert Support

Health professionals and advocacy groups have welcomed the decision. Professor Peter Johnson, NHS England’s national clinical director for cancer, called the treatment “life-changing.”

“This gives people with myeloma more precious time with their loved ones,” he said.

Shelagh McKinlay from the charity Myeloma UK added:

“This is fantastic news. We’ve been working hard to get this treatment approved – it will transform lives.”

NHS at the Forefront of Innovation

With this approval, the NHS continues to lead globally in offering cutting-edge cancer care. Health minister Karin Smyth praised the decision as a sign of the UK’s commitment to pioneering medical innovation.

“By harnessing ‘Trojan horse’ technology, we’re offering new hope to blood cancer patients across the country,” she said.

What is Multiple Myeloma?
Multiple myeloma is a cancer of plasma cells found in the bone marrow. It can cause bone pain, fatigue, and increased risk of infections. While incurable, treatments can help manage symptoms and extend life.

Know the Signs:
If you or someone you know experiences unexplained bone pain, frequent infections, or extreme tiredness, speak to a GP. Early diagnosis can improve treatment options and outcomes.

Want to Learn More or Support the Cause?
Visit Myeloma UK for resources, support, and up-to-date information about research and treatments.